Notice - Prescription Drug List (PDL): Lovastatin
The purpose of this Notice of Amendment is to announce the revised listing for lovastatin on the Prescription Drug List (PDL). As stated in the Notice of Intent to Amend, posted June 4, 2014, the revision will allow lovastatin to be marketed as a nonprescription product. Only the Human part of the PDL has been revised.
- Publisher - Current Organization Name: Health Canada
- Licence: Open Government Licence - Canada
Data and Resources
Notice - Prescription Drug List (PDL): LovastatinHTMLEnglish publication HTML
Notice - Prescription Drug List (PDL): LovastatinHTMLFrench publication HTML